Date | Title | Description | Source |
14.03.2024 | AstraZeneca Acquisition Brings Drug to Fill a Rare Disease G... | AstraZeneca is bolstering its rare disease pipeline with a deal to buy Amolyt Pharma, a biotech comp... | medcitynew... |
03.03.2024 | 'There's an enormous catch-up trade': These 5 small-cap stoc... | Markets 'There's an enormous catch-up trade': These 5 small-cap stocks are destined to soar, accordi... | businessin... |
31.01.2024 | Ascendis Pharma to Report Full Year 2023 Financial Results a... | COPENHAGEN, Denmark, Jan. 31, 2024 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (Nasdaq: ASND) today anno... | einpresswi... |
31.01.2024 | Ascendis Pharma Launches 2nd TransCon™ Product: YORVIPATH® N... | COPENHAGEN, Denmark, Jan. 31, 2024 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (Nasdaq: ASND) today anno... | einpresswi... |
16.11.2023 | Once-Weekly TransCon™ CNP Achieved Primary Efficacy Objectiv... | SHANGHAI, Nov. 16, 2023 /PRNewswire/ -- VISEN Pharmaceuticals (VISEN), an innovative biopharmaceutic... | en.prnasia... |
05.06.2023 | Ascendis Pharma Opens Compassionate Use Program for TransCon... | /EIN News/ -- – Compassionate use enables treating physicians in Germany to request access to invest... | einpresswi... |
31.05.2023 | Ascendis Pharma Oncology Program Update Highlights Latest Cl... | /EIN News/ -- – TransCon IL-2 β/γ in Phase 1 clinical trial showed monotherapy clinical activity in ... | einpresswi... |
25.05.2023 | Ascendis Pharma to Host Oncology Program Update on May 31 | /EIN News/ -- COPENHAGEN, Denmark, May 25, 2023 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (Nasdaq: ASN... | einpresswi... |
13.05.2023 | Ascendis Pharma Showcases Commitment to Rare Endocrine Disea... | /EIN News/ -- COPENHAGEN, Denmark, May 13, 2023 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (Nasdaq: ASN... | einpresswi... |
03.05.2023 | Ascendis Pharma to Participate in the BofA Securities 2023 H... | /EIN News/ -- COPENHAGEN, Denmark, May 03, 2023 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (Nasdaq: ASN... | einpresswi... |
07.02.2023 | Ascendis Pharma Announces Full Year 2022 Financial Results a... | /EIN News/ -- COPENHAGEN, Denmark, Feb. 07, 2023 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (Nasdaq: AS... | einpresswi... |
04.01.2023 | Online Enrollment Now Open for Physicians Requesting Expande... | /EIN News/ -- - The Expanded Access Program (EAP) allows physicians to request access to TransCon PT... | einpresswi... |
22.11.2022 | Ascendis Pharma to Participate in the 5th Annual Evercore IS... | /EIN News/ -- COPENHAGEN, Denmark, Nov. 22, 2022 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (Nasdaq: AS... | einpresswi... |
11.11.2022 | Dose Escalation Data from transcendIT-101, Ascendis Pharma’s... | /EIN News/ -- - Early signs of clinical activity were observed in patients receiving TransCon TLR7/8... | einpresswi... |
31.10.2022 | FDA Accepts for Priority Review Ascendis Pharma’s NDA for Tr... | - PDUFA target action date is April 30, 2023
- MAA submission to EMA on track for this quarter
COPEN... | globenewsw... |
26.10.2022 | Ascendis Pharma A/S Announces Third Quarter 2022 Financial R... | /EIN News/ -- COPENHAGEN, Denmark, Oct. 26, 2022 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (Nasdaq: AS... | einpresswi... |
26.10.2022 | Ascendis Pharma A/S Announces Third Quarter 2022 Financial R... | COPENHAGEN, Denmark, Oct. 26, 2022 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (Nasdaq: ASND) announced ... | globenewsw... |
03.10.2022 | Ascendis Pharma Announces Recommended Phase 2 Dose and Cohor... | - TransCon TLR7/8 Agonist continued to be well-tolerated and demonstrated early signs of clinical ac... | globenewsw... |
12.09.2022 | New Long-Term Data in Adult Patients with Hypoparathyroidism... | - Durability of response to TransCon PTH therapy through Week 110 demonstrated by continued normaliz... | globenewsw... |
01.09.2022 | Ascendis Pharma A/S Announces Upcoming Investor Presentation... | COPENHAGEN, Denmark, Sept. 01, 2022 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (Nasdaq: ASND) announced... | globenewsw... |
31.08.2022 | Ascendis Pharma Submits TransCon™ PTH New Drug Application t... | • TransCon PTH could, if approved, become the first hormone replacement therapy to address the under... | globenewsw... |
10.08.2022 | Ascendis Pharma A/S Reports Second Quarter 2022 Financial Re... | — U.S. regulatory submission for TransCon PTH, designed to be the first parathyroid hormone replacem... | globenewsw... |
04.08.2022 | Ascendis Pharma A/S Announces Second Quarter 2022 Financial ... | COPENHAGEN, Denmark, Aug. 04, 2022 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (Nasdaq: ASND) announced ... | globenewsw... |
07.06.2022 | Ascendis Pharma A/S Announces Two Oral Presentations Highlig... | – Late-breaker oral presentation of TransCon PTH Phase 3 PaTHway Trial data in adult hypoparathyroid... | globenewsw... |
23.05.2022 | Ascendis Pharma A/S Announces New Commercial Endocrinology L... | - Joe Kelly has been appointed to the newly created role of Head of U.S. Commercial, Endocrinology
-... | globenewsw... |
23.05.2022 | Positive Results from VISEN’s Phase 3 Trial of Once-Weekly T... | - VISEN’s Phase 3 Trial achieved primary endpoint; pediatric growth hormone deficiency (GHD) patient... | globenewsw... |
11.05.2022 | Ascendis Pharma A/S Reports First Quarter 2022 Financial Res... | Phase 3 PaTHway Trial top-line results demonstrated potential of TransCon™ PTH to become the first p... | globenewsw... |
09.05.2022 | Ascendis Pharma A/S to Participate in the BofA Securities 20... | COPENHAGEN, Denmark, May 09, 2022 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (Nasdaq: ASND) announced t... | globenewsw... |
04.05.2022 | Ascendis Pharma A/S Announces First Quarter 2022 Financial R... | COPENHAGEN, Denmark, May 04, 2022 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (Nasdaq: ASND) announced t... | globenewsw... |
01.05.2022 | Ascendis Pharma A/S to Present New Endocrinology Results at ... | New data highlights include:
- Phase 3 open-label extension study data for growth hormone-deficient ... | globenewsw... |
13.03.2022 | Ascendis Pharma A/S Announces Phase 3 PaTHway Trial of Trans... | – For the primary composite endpoint, TransCon PTH demonstrated a response rate of 78.7% compared to... | globenewsw... |
02.03.2022 | Ascendis Pharma A/S Reports Full Year 2021 Financial Results... | - Top-line results from PaTHway, a Phase 3 randomized study evaluating the safety, tolerability, and... | globenewsw... |
25.02.2022 | Ascendis Pharma A/S Announces Full Year 2021 Financial Resul... | COPENHAGEN, Denmark, Feb. 25, 2022 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (Nasdaq: ASND) today anno... | globenewsw... |
11.02.2022 | Ascendis Pharma A/S to Participate in the 11th Annual SVB Le... | COPENHAGEN, Denmark, Feb. 10, 2022 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (Nasdaq: ASND) today anno... | marketscre... |
10.02.2022 | Ascendis Pharma A/S to Participate in the 11th Annual SVB Le... | COPENHAGEN, Denmark, Feb. 10, 2022 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (Nasdaq: ASND) today anno... | globenewsw... |
13.01.2022 | Ascendis Pharma A/S Receives European Approval for TransCon™... | COPENHAGEN, Denmark, Jan. 13, 2022 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (Nasdaq: ASND) today anno... | globenewsw... |
10.01.2022 | Ascendis Pharma A/S Provides Update on Vision 3x3 Strategic ... | COPENHAGEN, Denmark, Jan. 10, 2022 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (Nasdaq: ASND) today anno... | globenewsw... |
04.01.2022 | Ascendis Pharma A/S to Participate in 40th Annual J.P. Morga... | COPENHAGEN, Denmark, Jan. 04, 2022 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (Nasdaq: ASND) today anno... | globenewsw... |
04.01.2022 | Ascendis Pharma A/S to Participate in 40th Annual J.P. Morga... | COPENHAGEN, Denmark, Jan. 04, 2022 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (Nasdaq: ASND) today anno... | marketscre... |
14.12.2021 | Ascendis Pharma A/S Virtual R&D Program Update Highlight... | –– TransCon™ PTH Phase 3 topline results expected in Q1 2022 and, if positive, planned NDA submissio... | globenewsw... |
07.12.2021 | Ascendis Pharma A/S to Host Virtual R&D Program Update o... | COPENHAGEN, Denmark, Dec. 07, 2021 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (Nasdaq: ASND) today anno... | globenewsw... |
19.11.2021 | Ascendis Pharma A/S Announces Top-Line Results from Week 84 ... | –– 58 of the original 59 subjects continue in the open-label extension portion of the Phase 2 trial.... | marketscre... |
18.11.2021 | Ascendis Pharma A/S Announces Top-Line Results from Week 84 ... | –– 58 of the original 59 subjects continue in the open-label extension portion of the Phase 2 trial.... | globenewsw... |
17.11.2021 | Ascendis Pharma A/S to Participate in the Evercore ISI 4th A... | COPENHAGEN, Denmark, Nov. 17, 2021 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (Nasdaq: ASND) today anno... | globenewsw... |
15.11.2021 | Ascendis Pharma A/S - Share Repurchase Program Update | COPENHAGEN, Denmark, Nov. 15, 2021 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (Nasdaq: ASND) today prov... | globenewsw... |
12.11.2021 | Ascendis Pharma A/S Receives Positive CHMP Opinion for Trans... | – TransCon hGH is a once-weekly prodrug of somatropin designed to reduce the treatment burden for pa... | globenewsw... |
12.11.2021 | Ascendis Pharma A/S Receives Positive CHMP Opinion for Trans... | – TransCon hGH is a once-weekly prodrug of somatropin designed to reduce the treatment burden for pa... | marketscre... |
11.11.2021 | Ascendis Pharma A/S Reports Third Quarter 2021 Financial Res... | Ascendis Pharma A/S Reports Third Quarter 2021 Financial Results
- SKYTROFA® (lonapegsomatropin-tcgd... | marketscre... |
11.11.2021 | Ascendis Pharma A/S Reports Third Quarter 2021 Financial Res... | – SKYTROFA® (lonapegsomatropin-tcgd) approved by the FDA in the U.S. as a once-weekly treatment for ... | marketscre... |
10.11.2021 | Ascendis Pharma A/S Reports Third Quarter 2021 Financial Res... | – SKYTROFA® (lonapegsomatropin-tcgd) approved by the FDA in the U.S. as a once-weekly treatment for ... | globenewsw... |
09.11.2021 | Ascendis Pharma A/S Presents New Non-Clinical Data for Trans... | - In non-clinical models, a single dose of TransCon™ TLR7/8 Agonist activated critical innate and ad... | globenewsw... |
08.11.2021 | Ascendis Pharma A/S - Share Repurchase Program Update | COPENHAGEN, Denmark, Nov. 08, 2021 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (Nasdaq: ASND) today prov... | globenewsw... |
03.11.2021 | Ascendis Pharma A/S Announces Third Quarter 2021 Financial R... | COPENHAGEN, Denmark, Nov. 03, 2021 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (Nasdaq: ASND), today ann... | globenewsw... |
15.10.2021 | Ascendis Pharma A/S Announces U.S. Commercial Launch of SKYT... | COPENHAGEN, Denmark, Oct. 15, 2021 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (Nasdaq: ASND), today ann... | globenewsw... |
30.09.2021 | Ascendis Pharma A/S : A/S Announces Presentations for TransC... | – Late-breaking oral presentation will feature a comprehensive review of 58-week results from the co... | marketscre... |
29.09.2021 | Ascendis Pharma A/S announces an Equity Buyback for 300,000 ... | Ascendis Pharma A/S (NasdaqGS:ASND) announces a share repurchase program. Under the program, the com... | marketscre... |
22.09.2021 | Ascendis Pharma A/S Announces Mean Bone Mineral Density (BMD... | – Data from subjects with available dual energy x-ray absorptiometry (DXA) scans demonstrated stabil... | marketscre... |
08.09.2021 | Ascendis Pharma A/S Announces Upcoming Investor Presentation... | COPENHAGEN, Denmark, Sept. 07, 2021 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (Nasdaq: ASND), a biopha... | marketscre... |
08.09.2021 | Ascendis Pharma A/S Submits Investigational New Drug Applica... | – TransCon IL-2 β/γ is an investigational long-acting prodrug designed to improve cancer immunothera... | marketscre... |
02.09.2021 | Ascendis Pharma A/S Announces Pricing of Public Offering of ... | COPENHAGEN, Denmark, Sept. 01, 2021 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (Nasdaq: ASND), a biopha... | marketscre... |
31.08.2021 | Ascendis Pharma A/S Announces Proposed Public Offering of AD... | COPENHAGEN, Denmark, Aug. 31, 2021 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (Nasdaq: ASND), a biophar... | marketscre... |
25.08.2021 | Ascendis Pharma A/S Reports Second Quarter 2021 Financial Re... | – Announced U.S. Food and Drug Administration Approval of SKYTROFA® (lonapegsomatropin-tcgd), the Fi... | marketscre... |
25.08.2021 | Ascendis Pharma A/S Announces U.S. Food and Drug Administrat... | - SKYTROFA, the first FDA approved treatment utilizing TransCon™ technology, is a long-acting prodru... | marketscre... |
12.06.2021 | ASCENDIS PHARMA A/S
Ascendis Pharma A/S Announces Extension... | COPENHAGEN, Denmark, June 11, 2021 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (Nasdaq: ASND), a biophar... | marketscre... |
28.05.2021 | ASCENDIS PHARMA A/S
Ascendis Pharma A/S Invites the Public ... | COPENHAGEN, Denmark, May 28, 2021 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (Nasdaq: ASND), a biopharm... | marketscre... |
27.05.2021 | Ascendis Pharma A/S Reports First Quarter 2021 Financial Res... | – Pre-launch activities continue in preparation for a potential FDA approval of TransCon™ hGH (lonap... | marketscre... |
17.05.2021 | ASCENDIS PHARMA A/S
Ascendis Pharma A/S Announces First Qua... | COPENHAGEN, Denmark, May 17, 2021 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (Nasdaq: ASND), a biopharm... | marketscre... |
12.05.2021 | ASCENDIS PHARMA A/S
Ascendis Pharma A/S Announces Expansion... | COPENHAGEN, Denmark, May 12, 2021 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (Nasdaq: ASND), a biopharm... | marketscre... |
06.05.2021 | ASCENDIS PHARMA A/S
Ascendis Pharma A/S Announces Presentat... | COPENHAGEN, Denmark, May 06, 2021 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (Nasdaq: ASND), a biopharm... | marketscre... |
04.05.2021 | ASCENDIS PHARMA A/S
Ascendis Pharma A/S Announces Participa... | COPENHAGEN, Denmark, May 04, 2021 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (Nasdaq: ASND), a biopharm... | marketscre... |
21.04.2021 | ASCENDIS PHARMA A/S
Ascendis Pharma A/S Announces Presentat... | COPENHAGEN, Denmark, April 21, 2021 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (Nasdaq: ASND), a biopha... | marketscre... |
30.03.2021 | ASCENDIS PHARMA A/S
Ascendis Pharma A/S Announces Participa... | COPENHAGEN, Denmark, March 30, 2021 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (Nasdaq: ASND), a biopha... | marketscre... |
15.03.2021 | Ascendis Pharma A/S Announces Participation at Oppenheimer 3... | COPENHAGEN, Denmark, March 15, 2021 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (Nasdaq: ASND), a biopha... | globenewsw... |
11.03.2021 | Ascendis Pharma A/S Reports Full Year 2020 Financial Results | – Preparations for potential launch of first Endocrinology Rare Disease product candidate, TransCon ... | marketscre... |
10.03.2021 | Ascendis Pharma A/S Announces Seven Presentations at ENDO 20... | COPENHAGEN, Denmark, March 10, 2021 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (Nasdaq: ASND), a biopha... | globenewsw... |
04.03.2021 | Ascendis Pharma A/S Announces Full Year 2020 Financial Resul... | COPENHAGEN, Denmark, March 04, 2021 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (Nasdaq: ASND), a biopha... | globenewsw... |
26.02.2021 | Ascendis Pharma A/S Announces New “Outgrow GHD” Educational ... | COPENHAGEN, Denmark, Feb. 26, 2021 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (Nasdaq: ASND), a biophar... | globenewsw... |
18.02.2021 | Ascendis Pharma A/S Announces Participation at SVB Leerink 1... | COPENHAGEN, Denmark, Feb. 18, 2021 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (Nasdaq: ASND), a biophar... | globenewsw... |
19.10.2016 | Ascendis nets $112M for PhIII growth hormone trial | Ascendis Pharma ($ASND) is aiming to raise at least $112 million (€102 million) to move its long-act... | fiercebiot... |
29.06.2016 | The biotech IPO feast flags as investors lose their appeti... | There was a time after the 2008 crash that biotech IPOs were about as popular as snow in March. B... | endpts.com... |
29.01.2015 | Ascendis Pharma Raises $108M in IPO | Copenhagen, Denmark-based biotech company Ascendis Pharma (Nasdaq: ASND) raised $108m for its IPO af... | finsmes.co... |
01.12.2014 | Ascendis banks $60M to get its orphan drug into Phase III | Danish biotech Ascendis Pharma has put together a $60 million D round, cash that'll help get its onc... | fiercebiot... |
01.12.2014 | Ascendis Pharma Completes $60M Series D Financing | Ascendis Pharma A/S, a Hellerup, Denmark- Palo Alto, California- and Heidelberg, Germany-based biote... | finsmes.co... |
01.12.2014 | Ascendis Pharma AS Completes $60 Million Oversubscribed Seri... | Utrecht, The Netherlands and Copenhagen, Denmark - Ascendis Pharma A/S, a biopharmaceutical company ... | gildehealt... |
26.11.2013 | Ascendis Completes $33m Medical Devices Acquisition | Healthcare group, Ascendis has secured its first acquisition in a $33 million buyout of Surgical Inn... | venturesaf... |
13.12.2007 | Life sciences briefing: Thursday, Dec. 13, 2007 | TODAY’S HEADLINES:
Fovea Pharma sees €30M for eye drugs (release)
Ascendis Pharma raises €18M for ti... | venturebea... |